Gao Chunyan, Xie Rui, Yu Chengyuan, Ma Ruishuang, Dong Weijun, Meng Huan, Zhang Yan, Si Yu, Zhang Zhuo, Novakovic Valerie, Zhang Yong, Kou Junjie, Bi Yayan, Li Baoxin, Xie Rujuan, Gilbert Gary E, Zhou Jin, Shi Jialan
Department of Hematology, The First Hospital, Harbin Medical University, Harbin, China.
Department of Medical Laboratory Science and Technology, Harbin Medical University-Daqing, Daqing, China.
PLoS One. 2015 Nov 16;10(11):e0142835. doi: 10.1371/journal.pone.0142835. eCollection 2015.
The mechanisms contributing to an increased risk of thrombosis in uremia are complex and require clarification. There is scant morphological evidence of membrane-dependent binding of factor Xa (FXa) and factor Va (FVa) on endothelial cells (EC) in vitro. Our objectives were to confirm that exposed phosphatidylserine (PS) on microparticle (MP), EC, and peripheral blood cell (PBC) has a prothrombotic role in uremic patients and to provide visible and morphological evidence of PS-dependent prothrombinase assembly in vitro. We found that uremic patients had more circulating MP (derived from PBC and EC) than controls. Additionally, patients had more exposed PS on their MPs and PBCs, especially in the hemodialysis group. In vitro, EC exposed more PS in uremic toxins or serum. Moreover, reconstitution experiments showed that at the early stages, PS exposure was partially reversible. Using confocal microscopy, we observed that PS-rich membranes of EC and MP provided binding sites for FVa and FXa. Further, exposure of PS in uremia resulted in increased generation of FXa, thrombin, and fibrin and significantly shortened coagulation time. Lactadherin, a protein that blocks PS, reduced 80% of procoagulant activity on PBC, EC, and MP. Our results suggest that PBC and EC in uremic milieu are easily injured or activated, which exposes PS and causes a release of MP, providing abundant procoagulant membrane surfaces and thus facilitating thrombus formation. Blocking PS binding sites could become a new therapeutic target for preventing thrombosis.
导致尿毒症患者血栓形成风险增加的机制复杂,需要进一步阐明。目前体外几乎没有形态学证据表明内皮细胞(EC)上存在因子Xa(FXa)和因子Va(FVa)的膜依赖性结合。我们的目的是证实微粒(MP)、内皮细胞和外周血细胞(PBC)上暴露的磷脂酰丝氨酸(PS)在尿毒症患者中具有促血栓形成作用,并在体外提供PS依赖性凝血酶原酶组装的可见形态学证据。我们发现,与对照组相比,尿毒症患者循环中的MP(来源于PBC和EC)更多。此外,患者的MP和PBC上暴露的PS更多,尤其是在血液透析组。在体外,尿毒症毒素或血清中的内皮细胞暴露更多的PS。此外,重组实验表明,在早期阶段,PS暴露部分是可逆的。使用共聚焦显微镜,我们观察到内皮细胞和MP富含PS的膜为FVa和FXa提供了结合位点。此外,尿毒症患者PS的暴露导致FXa、凝血酶和纤维蛋白生成增加,凝血时间显著缩短。Lactadherin是一种能阻断PS的蛋白质,可降低PBC、内皮细胞和MP上80%的促凝活性。我们的结果表明,尿毒症环境中的PBC和内皮细胞容易受损或激活,从而暴露PS并导致MP释放,提供丰富的促凝膜表面,从而促进血栓形成。阻断PS结合位点可能成为预防血栓形成的新治疗靶点。